Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taisho: Sales Down 1.1% due to Slump of OTC Drugs
June 3, 2002
- NEW PRODUCTS
June 3, 2002
- Banyu: Nu-lotan Contributes to Good Sales, Profits
June 3, 2002
- 9 Drugs Including Elaspol to Be Included in NHI List
June 3, 2002
- Neoral Reduces Kidney Rejection Rates: MO2ART Study
May 27, 2002
- Worker Consultation Service Receives 5,398 Calls: LWC Survey
May 27, 2002
- Kainos: Automatic ELISA System for Microplates
May 27, 2002
- Will the FY2002 Medical Fee Revision Promote Use of Generics? - Strategies of Major GE Makers - （1）
May 27, 2002
- Improvement of Nurse Training Recommended
May 27, 2002
- WEBSITE NEWS
May 27, 2002
- Will the FY2002 Medical Fee Revision Promote Use of Generics? - Strategies of Major GE Makers - （2）
May 27, 2002
- Nat'l Exam for Physicians to Be Made More Accessible to the Handicapped
May 27, 2002
- Terumo: Sales Up 6.3% to \187,082 Mil.
May 27, 2002
- Wholesalers to Assist Makers in Immediate PMS
May 27, 2002
- General Risk Managers Appointed at All Nat'l Univ. Hospitals
May 27, 2002
- Olympus: New Digital Microscope "MIC-D"
May 27, 2002
- Drug Sales Up 3.5% in FY2001: CR&C
May 27, 2002
- GL on Subarachnoidal Hemorrhage Compiled
May 27, 2002
- AstraZeneca PLC: 1st Qtr Sales Up 13% to US$4,421 Mil.
May 27, 2002
- Otsuka Pharma Factory Sues Shionogi Claiming Infringement of Design Right
May 27, 2002
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…